- Trials with a EudraCT protocol (20)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
20 result(s) found for: Macronutrients.
Displaying page 1 of 1.
EudraCT Number: 2017-002487-41 | Sponsor Protocol Number: GLY-321-2017 | Start Date*: 2018-01-31 | |||||||||||
Sponsor Name:GLyPharma Therapeutic Inc. (a wholly owned subsidiary of VectivBio Holding AG) | |||||||||||||
Full Title: A Phase Ib/IIa open-label, repeated dose, metabolic balance study of FE 203799 in patients with short bowel syndrome | |||||||||||||
Medical condition: Short bowel syndrome (SBS) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2008-008899-14 | Sponsor Protocol Number: LWH0776 | Start Date*: 2009-06-25 |
Sponsor Name:Liverpool Women's NHS Foundation Trust | ||
Full Title: Standardised, Concentrated, Additional Macronutrients, Parenteral (SCAMP) nutrition in very preterm infants: a phase IV randomised controlled study of macronutrient intake, growth and implications ... | ||
Medical condition: Prematurity | ||
Disease: | ||
Population Age: Preterm newborn infants, Under 18 | Gender: Male, Female | |
Trial protocol: GB (Completed) | ||
Trial results: View results |
EudraCT Number: 2020-005194-27 | Sponsor Protocol Number: ZP1848-20060 | Start Date*: 2021-06-30 | |||||||||||
Sponsor Name:Zealand Pharma A/S | |||||||||||||
Full Title: A Single-Center Phase 3b Trial Investigating the Long-term Effect on Intestinal Absorption, Nutritional Status and Long-Term Safety of treatment with Glepaglutide in Patients with Short Bowel Syndr... | |||||||||||||
Medical condition: Short bowel syndrome | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2004-000439-27 | Sponsor Protocol Number: CL0600-005 | Start Date*: 2007-10-29 |
Sponsor Name:NPS Allelix Corporation | ||
Full Title: A Study of the Safety and Efficacy of Teduglutide in Subjects with Parenteral Nutrition-Dependant Short Bowel Syndrome Who Completed Protocol CL0600-004 | ||
Medical condition: Short Bowel Syndrome (SBS) refers to the clinical situation whereby a significant reduction in the absorptive capacity of the intestine results from inadequate anatomical or functional length of re... | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DK (Completed) | ||
Trial results: View results |
EudraCT Number: 2020-005129-99 | Sponsor Protocol Number: TA799-013 | Start Date*: 2021-02-10 | |||||||||||
Sponsor Name:VectivBio AG | |||||||||||||
Full Title: A multicenter, open-label, metabolic balance study to evaluate the effects of apraglutide on intestinal absorption in adult subjects with short bowel syndrome, intestinal failure (SBS-IF), and colo... | |||||||||||||
Medical condition: short bowel syndrome, intestinal failure (SBS-IF), colon-in-continuity (CIC) | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) BE (Completed) DK (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2015-000825-35 | Sponsor Protocol Number: U1111-1167-2731 | Start Date*: 2015-08-27 | |||||||||||
Sponsor Name:Rigshospitalet Blegdamsvej | |||||||||||||
Full Title: The effect of the glucagon-like peptide-1 analogue, liraglutide (Victoza®), on jejunostomy output and intestinal absorption in short bowel syndrome patients, a double-blind cross-over study | |||||||||||||
Medical condition: Short bowel syndrome (SBS) is a clinical situation with reduced absorptive mucosal surface due to extensive surgical resection. SBS leads to increased intestinal losses of fluids and electrolytes; ... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2013-001347-31 | Sponsor Protocol Number: M13-954 | Start Date*: 2013-11-12 |
Sponsor Name:Abbott Laboratories GmbH | ||
Full Title: A Double-blind, Randomized, Multi-center, Placebo-controlled, Parallel-group Study to Assess the Effect of Creon® on Pancreatic Exocrine Insufficiency in Subjects with Diabetes Mellitus type 2 | ||
Medical condition: Pancreatic exocrine insufficiency in diabetes type II | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: ES (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2018-000754-22 | Sponsor Protocol Number: IBP-9414-020 | Start Date*: 2019-10-14 | |||||||||||
Sponsor Name:Infant Bacterial Therapeutics AB (IBT) | |||||||||||||
Full Title: A randomized, double blind, parallel-group, placebo controlled study to evaluate the efficacy and safety of IBP-9414 in premature infants 500-1500g birth weight in the prevention of necrotizing ent... | |||||||||||||
Medical condition: Necrotizing Enterocolitis (NEC) | |||||||||||||
|
|||||||||||||
Population Age: Preterm newborn infants, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) FR (Completed) HU (Completed) ES (Ongoing) BG (Completed) PL (Completed) RO (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2017-004394-14 | Sponsor Protocol Number: ZP1848-17111 | Start Date*: 2018-10-19 | |||||||||||
Sponsor Name:Zealand Pharma A/S | |||||||||||||
Full Title: A Phase 3, international, multicenter, randomized, double-blind, placebo-controlled trial to evaluate the efficacy and safety of glepaglutide in patients with short bowel syndrome (SBS) | |||||||||||||
Medical condition: Short bowel syndrome | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Completed) FR (Completed) GB (GB - no longer in EU/EEA) DE (Completed) BE (Completed) DK (Completed) PL (Completed) IT (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2009-016731-34 | Sponsor Protocol Number: CRO1413 | Start Date*: 2010-01-08 | |||||||||||
Sponsor Name:Imperial College | |||||||||||||
Full Title: Amino acid regimen and intravenous lipid composition in preterm parenteral nutrition: a randomised double blind controlled trial of Nutritional Evaluation and Optimisation in Neonates. | |||||||||||||
Medical condition: Preterm birth | |||||||||||||
|
|||||||||||||
Population Age: Preterm newborn infants, Newborns, Infants and toddlers, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2015-002826-38 | Sponsor Protocol Number: ZP1848-15073 | Start Date*: 2016-01-28 | |||||||||||
Sponsor Name:Zealand Pharma A/S | |||||||||||||
Full Title: A phase 2 trial testing ZP1848 in patients with SBS | |||||||||||||
Medical condition: Short Bowel Syndrome (SBS) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2004-000438-35 | Sponsor Protocol Number: CL 0600-004 | Start Date*: 2004-09-30 |
Sponsor Name:NPS Allelix Corporation | ||
Full Title: A study of the Efficacy and Safety of Teduglutide in subjects with Parenteral Nutritional Dependant Short Bowel Syndrome | ||
Medical condition: Short Bowel Syndrome (SBS) refers to the clinical situation whereby a significant reduction in the absorptive capacity of the intestine results from inadequate anatomical or functional length of re... | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DK (Completed) | ||
Trial results: View results |
EudraCT Number: 2018-002191-41 | Sponsor Protocol Number: AIDIT | Start Date*: Information not available in EudraCT |
Sponsor Name:Uppsala University | ||
Full Title: Azithromycin Insulin Diet Intervention Trial in Type 1 Diabetes | ||
Medical condition: Type 1 diabetes | ||
Disease: | ||
Population Age: Children, Under 18 | Gender: Male, Female | |
Trial protocol: SE (Prematurely Ended) | ||
Trial results: (No results available) |
EudraCT Number: 2015-000849-23 | Sponsor Protocol Number: HC-G-H-1403 | Start Date*: 2017-08-21 | |||||||||||
Sponsor Name:B. Braun Melsungen AG | |||||||||||||
Full Title: A RANDOMIZED, CONTROLLED, DOUBLE-BLIND, MULTICENTER CLINICAL TRIAL ON HOME PARENTERAL NUTRITION USING AN OMEGA-3 FATTY ACID ENRICHED MCT/LCT LIPID EMULSION | |||||||||||||
Medical condition: Chronic intestinal failure | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Completed) GB (GB - no longer in EU/EEA) | |||||||||||||
Trial results: View results |
EudraCT Number: 2018-001429-26 | Sponsor Protocol Number: ZP1848-17127 | Start Date*: 2019-05-08 | |||||||||||
Sponsor Name:Zealand Pharma A/S | |||||||||||||
Full Title: A Double-Blind Phase 3 Extension Trial Assessing the Long Term Safety and Efficacy of Glepaglutide in Patients with Short Bowel Syndrome (SBS) | |||||||||||||
Medical condition: Short bowel syndrome | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) FR (Trial now transitioned) DE (Trial now transitioned) BE (Trial now transitioned) DK (Completed) PL (Trial now transitioned) NL (Trial now transitioned) IT (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2013-002819-10 | Sponsor Protocol Number: M13-621 | Start Date*: 2013-11-29 |
Sponsor Name:Abbott Laboratories GmbH | ||
Full Title: A Double-blind, Randomized, Multicenter, Cross-over Study to Compare the Effect of Creon N and Creon® on Fat Digestion in Subjects ≥ 12 years of Age with Pancreatic Exocrine Insufficiency Due to Cy... | ||
Medical condition: Pancreatic exocrine Insufficiency due to Cystic Fibrosis | ||
Disease: | ||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | |
Trial protocol: HU (Completed) ES (Completed) | ||
Trial results: View results |
EudraCT Number: 2017-000530-54 | Sponsor Protocol Number: VS56151/17000277 | Start Date*: 2018-01-16 | |||||||||||||||||||||
Sponsor Name:University of Copenhagen | |||||||||||||||||||||||
Full Title: The effect of cannibinols in patients with pancreatic cancer in the palliative state | |||||||||||||||||||||||
Medical condition: Pancreatic cancer | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: DK (Completed) | |||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2018-003831-31 | Sponsor Protocol Number: MS1819/18/02 | Start Date*: 2019-03-28 | |||||||||||
Sponsor Name:AzurRx | |||||||||||||
Full Title: A multicenter, open-label Phase 2 study with escalating doses of MS1819-SD on top of a stable dose of PPEs, to investigate the efficacy and safety of this combination for the compensation of severe... | |||||||||||||
Medical condition: Exocrine Pancreatic Insufficiency | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: HU (Completed) ES (Prematurely Ended) PL (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2015-002739-17 | Sponsor Protocol Number: AN-EPI3331 | Start Date*: 2015-12-30 |
Sponsor Name:ANTHERA Pharmaceuticals, Inc. | ||
Full Title: A Phase 3, Randomized, Open-Label, Assessor-Blind, Non-Inferiority, Active Comparator Study Evaluating the Efficacy and Safety of Liprotamase in Subjects with Cystic Fibrosis-Related Exocrine Pancr... | ||
Medical condition: Pancreatic exocrine Insufficiency due to Cystic Fibrosis | ||
Disease: | ||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | |
Trial protocol: HU (Completed) CZ (Completed) ES (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2014-004519-35 | Sponsor Protocol Number: PANC2002 | Start Date*: 2015-01-09 |
Sponsor Name:Abbott Laboratories GmbH | ||
Full Title: A Phase II, Multicenter, Parallel-Group, Active-Controlled, Randomized, Double-blind, Dose-Ranging Study to Evaluate the Efficacy and Safety of Different Doses of Creon IR in Subjects with Pancreat... | ||
Medical condition: Pancreatic exocrine Insufficiency due to Cystic Fibrosis | ||
Disease: | ||
Population Age: Adolescents, Under 18, Adults | Gender: Male, Female | |
Trial protocol: HU (Completed) CZ (Completed) ES (Completed) GB (Prematurely Ended) | ||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
